title: Impact of redefining acute myocardial infarction on incidence, management and reimbursement rate of acute coronary syndromes.
abstract: BACKGROUND
  Although redefinition for acute myocardial infarction (AMI) has been proposed few years ago, to date it has not been universally adopted by many institutions. The purpose of this study is to evaluate the diagnostic, prognostic and economical impact of the new diagnostic criteria for AMI.
  
  
  METHODS
  Patients consecutively admitted to the emergency department with suspected acute coronary syndromes were enrolled in this study. Troponin T (cTnT) was measured in samples collected for routine CK-MB analyses and results were not available to physicians. Patients without AMI by traditional criteria and cTnT > or = 0.035 ng/mL were coded as redefined AMI. Clinical outcomes were hospital death, major cardiac events and revascularization procedures. In-hospital management and reimbursement rates were also analyzed.
  
  
  RESULTS
  Among 363 patients, 59 (16%) patients had AMI by conventional criteria, whereas additional 75 (21%) had redefined AMI, an increase of 127% in the incidence. Patients with redefined AMI were significantly older, more frequently male, with atypical chest pain and more risk factors. In multivariate analysis, redefined AMI was associated with 3.1 fold higher hospital death (95% CI: 0.6-14) and a 5.6 fold more cardiac events (95% CI: 2.1-15) compared to those without AMI. From hospital perspective, based on DRGs payment system, adoption of AMI redefinition would increase 12% the reimbursement rate [3552 Int dollars per 100 patients evaluated].
  
  
  CONCLUSIONS
  The redefined criteria result in a substantial increase in AMI cases, and allow identification of high-risk patients. Efforts should be made to reinforce the adoption of AMI redefinition, which may result in more qualified and efficient management of ACS.
authors.affiliation: Cardiology Division, Hospital de Clínicas de Porto Alegre, Brazil. cpolanczyk@hcpa.ufgs.br
authors.forename: Carísi A
authors.initials: CA
authors.lastname: Polanczyk
authors.forename: Samir
authors.initials: S
authors.lastname: Schneid
authors.forename: Betina V
authors.initials: BV
authors.lastname: Imhof
authors.forename: Mariana
authors.initials: M
authors.lastname: Furtado
authors.forename: Carolina
authors.initials: C
authors.lastname: Pithan
authors.forename: Luis E
authors.initials: LE
authors.lastname: Rohde
authors.forename: Jorge P
authors.initials: JP
authors.lastname: Ribeiro
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D003327:Coronary Disease / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D052279:Creatine Kinase, MB Form / Q000097:blood; D003937:Diagnosis, Differential; D018588:Fee-for-Service Plans; D005260:Female; D017048:Health Care Costs; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013577:Syndrome; D020107:Troponin T / Q000097:blood
chemical_list: D015415:Biomarkers; D020107:Troponin T; D052279:Creatine Kinase, MB Form